Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
Warts, Genital · Neoplasms, Anal
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 1,059 (final count)
- Started
- Nov 30, 2020
- Main results expected
- Dec 31, 2023
- Fully finished
- Jul 23, 2025
- Results posted
- Jan 13, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Base Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection
Measured over: Up to approximately 36 Months
Base Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
Measured over: Up to 5 days after any vaccination
Base Study: Percentage of Participants With ≥1 Systemic AE
Measured over: Up to 15 days after any vaccination
Base Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)
Measured over: Up to approximately 37 months
Base Study: Number of Participants With Elevated Oral Body Temperature
Measured over: Up to 5 days after any vaccination
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04635423 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC